Literature DB >> 15983388

Intracellular signal transduction pathway proteins as targets for cancer therapy.

Alex A Adjei1, Manuel Hidalgo.   

Abstract

Circulating cytokines, hormones, and growth factors control all aspects of cell proliferation, differentiation, angiogenesis, apoptosis, and senescence. These chemical signals are propagated from the cell surface to intracellular processes via sequential kinase signaling, arranged in modules that exhibit redundancy and cross talk. This signal transduction system comprising growth factors, transmembrane receptor proteins, and cytoplasmic secondary messengers is often exploited to optimize tumor growth and metastasis in malignancies. Thus, it represents an attractive target for cancer therapy. This review will summarize current knowledge of selected intracellular signaling networks and their role in cancer therapy. The focus will be on pathways for which inhibitory agents are currently undergoing clinical testing. Original data for inclusion in this review were identified through a MEDLINE search of the literature. All papers from 1966 through March 2005 were identified by the following search terms: "signal transduction," "intracellular signaling," "kinases," "proliferation," "growth factors," and "cancer therapy." All original research and review papers related to the role of intracellular signaling in oncogenesis and therapeutic interventions relating to abnormal cell signaling were identified. This search was supplemented by a manual search of the Proceedings of the Annual Meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and the American Association for Cancer Research (AARC)--European Organisation for Research and Treatment of Cancer (EORTC)--National Cancer Institute (NCI) Symposium on New Anticancer Drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983388     DOI: 10.1200/JCO.2005.23.648

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  53 in total

1.  Association of PTEN gene polymorphisms with liver cancer risk.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 2.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

3.  Revealing global regulatory perturbations across human cancers.

Authors:  Hani Goodarzi; Olivier Elemento; Saeed Tavazoie
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

Review 4.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

Review 5.  HtrA serine proteases as potential therapeutic targets in cancer.

Authors:  Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

7.  Late presentation of sorafenib-associated rash: a case report.

Authors:  Thomas Sarkodie; Paul Ross
Journal:  J Med Case Rep       Date:  2010-10-25

8.  Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: a case report and review of literature.

Authors:  Jigarkumar Parikh; Teresa Coleman; Nidia Messias; James Brown
Journal:  Rare Tumors       Date:  2009-12-28

9.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15

10.  Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma.

Authors:  Chun-Nan Yeh; See-Tong Pang; Tsung-Wen Chen; Ren-Ching Wu; Wen-Hui Weng; Miin-Fu Chen
Journal:  BMC Cancer       Date:  2009-07-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.